Therapeutic Response

PD-L1 >= 50% status confers therapeutic sensitivity to Pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.